Evaluation of Potencies of Different Brands of Piroxicam in Wistar Rats

Submission Deadline-30th April 2024
April 2024 Issue : Publication Fee: 30$ USD Submit Now
Submission Deadline-20th April 2024
Special Issue of Education: Publication Fee: 30$ USD Submit Now

International Journal of Research and Innovation in Applied Science (IJRIAS) | Volume VI, Issue IX, September 2021|ISSN 2454-6194

Evaluation of Potencies of Different Brands of Piroxicam in Wistar Rats

 Lemii, B. Cletus1*, Owunari, A. Georgewill2
1Department of Pharmacology and Therapeutics, Faculty of Basic Clinical Sciences, College of Medical Sciences, Rivers State University, Port Harcourt, Nigeria
2Department of pharmacology, Faculty of Basic Clinical Sciences, College of Health Sciences, University of Port Harcourt, Port Harcourt, Nigeria
Corresponding Author*

IJRISS Call for paper

Abstract: Background: Piroxicam is one of non-steroidal anti-inflammatory drug (NSAID), commonly used because of single daily regimen which eases compliance and had complaints on the significant dissimilarities in the physico-chemical properties across various brands. This study aimed at evaluating the potencies and toxicity profiles of different brands of Piroxicam in male Wistar rats. Healthy ninety (90) male Wistar rats, weighing between 180 and 230grams were procured from the animal house of the Pharmacology department, Faculty of Basic Clinical Sciences in University of Port Harcourt, Nigeria. METHODS: The animals were allocated into six (6) groups of five (5) animals each, for each experimental phase -Group1-control group, 2 to 6 –treatment groups. The experiment involved three different phases: anti-inflammation, anti-pyrexia and analgesia. Experimental inflammatory, pyretic and pain situations were induced on the study animals using egg albumin (0.1ml, 20% in 0.9% normal saline), 60% baker’s yeast (1ml/100g rats’ body weight), and analgesimeter respectively. Thereafter, the clinical dose (0.285mg/kg) of Piroxicam brands (A Brand, B Brand, C Brand, D Brand and E Brand) were administered on treatment groups. The dose-effect of the Piroxicam brands were observed at different times (0, 30, 60, and 120, 180 and 240 minutes). RESULTS: Result reveals that, the five Piroxicam brands demonstrated significant (p<0.05) anti-inflammatory, antipyretic and analgesic potencies with variance in these properties. Thus, outcome indicated graded significant (p<0.05) variations as follows: anti-inflammatory potencies―D Brand > A Brand > B Brand >C Brand>E Brand; Anti-pyretic potencies― C Brand>B Brand>E Brand>A Brand>D Brand. Analgesic potencies ― B Brand>E Brand>C Brand>D Brand>A Brand. CONCLUSION: The overall order of potencies of the stated brands indicated that B Brand>C Brand>E Brand>A Brand≥D Brand.

Keywords: potency, different brands of piroxicam